Appointment of Product Development Director

EDX Medical Group PLC

01 March 2024

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

EDX Medical Group plc

Appointment of Product Development Director

EDX Medical Group plc · EDX

1 March  2024

EDX Medical Group plc ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has today announced the appointment of Claire Bevis-Mott as Director of Product Development. Ms Bevis-Mott joins EDX Medical while the Company is accelerating development of new diagnostic products to help meet global demand from healthcare providers.

Mrs Bevis-Mott is a proven scientific leader in the life sciences sector, working in leadership and management positions with companies including Illumina Ltd where she worked for 17 years commercialising numerous products and received an "Accomplished Inventor" award as the most prolific female inventor   within the Product Development team.  Previously, she held a research post with the Medical Research Council.

Mrs Bevis-Mott commented: "I am excited to be joining the EDX Medical team which is clearly committed to bringing innovative diagnostic products to patients. The need for rapid diagnosis and personalised treatments across a wide range of diseases has never been greater. Having taken complex products to market, I have deep experience   in all phases of the product lifecycle and am passionate about the creation and delivery of novel solutions that can make a difference to patients."

Professor Sir Chris Evans OBE, founder of EDX Medical, commented: "We're thrilled to welcome Claire to EDX Medical as she has demonstrated over many years, particularly with a world leader in human genomics such as Illumina, a tremendous ability to develop class-leading testing products.  Claire's proven expertise in taking projects from laboratory into marketable products fits hand in glove with our vision to deliver the most advanced diagnostic tests to patients."

Dr Mike Hudson, CEO of EDX Medical, commented: "We are delighted that Claire is joining our international development team at a time when we are growing our portfolio of products and services. Her outstanding project management skills and understanding behind the technical delivery of complex genomic products will immediately enhance our ability to deliver 'best-in-class' innovative products."

The directors of EDX Medical accept responsibility for the contents of this announcement.

Contacts:

EDX Medical Group Plc	[phone]
Dr Mike Hudson (CEO)	[e-mail]
Oberon Capital	020 3179 5300
Nick Lovering (Corporate Adviser) Adam Pollock, Mike Seabrook (Corporate Broking)
Media House International	0207 710 0020
Ramsay Smith (Executive Director) Gary McQueen (Associate Director)	[e-mail] [phone] [e-mail] + 44 (0) 7834 694609

Notes for Editors:

About EDX Medical Group www.edxmedical.com                               

EDX Medical Group Plc develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiaries "Hutano Diagnostics Ltd", based in Oxford and "Torax Biosciences Ltd" in Ireland which together are pioneering the development of novel point of care tests.  

EDX Medical conducts test development and product validation to ISO 13485 and provides testing and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

 

END